Anticoagulant activities of piperlonguminine in vitro and in vivo

BMB Reports

Volumn 46, Issue 10, 2013, Pages 484-489

  Lee, Wonhwa ^a,b   Yoo, Hayoung ^a   Ku, Sae Kwang ^c   Kim, Jeong Ah ^a   Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Daegu Haany University   (South Korea)

Author keywords

Coagulation cascade; Endothelium; Fibrinolysis; Piperlonguminine

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; PIPERLONGUMININE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL; ARTICLE; BLEEDING; CELL CULTURE; DRUG EFFECT; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOUSE; PROTHROMBIN TIME; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTICOAGULANTS; CELLS, CULTURED; DIOXOLANES; FACTOR XA; HEMORRHAGE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED ICR; PROTHROMBIN TIME; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84886780687     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2013.46.10.028     Document Type: Article

References (30)

1. Dahlback, B. (2000) Blood coagulation. Lancet 355, 1627-1632.
2. Davie, E. W., Fujikawa, K. and Kisiel, W. (1991) The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30, 10363-10370.
3. Davie, E. W. (1995) Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 74, 1-6.
4. Li, Y., Qian, Z. J., Ryu, B., Lee, S. H., Kim, M. M. and Kim, S. K. (2009) Chemical components and its antioxidant properties in vitro: an edible marine brown alga, Ecklonia cava. Bioorg. Med. Chem. 17, 1963-1973.
5. Huang, H., Morgan, C. M., Asolkar, R. N., Koivunen, M. E. and Marrone, P. G. (2010) Phytotoxicity of sarmentine isolated from long pepper (Piper longum) fruit. J. Agric. Food Chem. 58, 9994-10000.
6. Manoj, P., Soniya, E. V., Banerjee, N. S. and Ravichandran, P. (2004) Recent studies on well-known spice, Piper longum Linn. Nat. Prod. Rad. 3, 222-227.
7. Rao, G. V., Rao, K. S., Mukhopadhyay, T. and Madhavi, M. S. L. (2012) Alkamides and their biological activity from Piper longum Linn. J. Pharm Res. 5, 165-168.
8. Parmar, V. S., Jain, S. C., Bisht, K. S., Jain, R., Taneja, P., Jha, A., Tyagi, O. D., Prasad, A. K., Wengel, J., Olsen, C. E. and Boll, P. M. (1997) Phytochemistry of the genus Piper. Phytochemistry 46, 597-673.
9. Chatterjee, A. and Dutta, C. P. (1967) Alkaloids of Piper longum Linn. I. Structure and synthesis of piperlongumine and piperlonguminine. Tetrahedron 23, 1769-1781.
10. Desai, S. J., Prabhu, B. R. and Mulchandani, N. B. (1988) Aristolactams and 4,5-dioxoaporphines from Piper longum. Phytochemistry 27, 1511-1515.
11. Liu, J., Bi, Y., Luo, R. and Wu, X. (2011) Simultaneous UFLC-ESI-MS/MS determination of piperine and piperlonguminine in rat plasma after oral administration of alkaloids from Piper longum L.: application to pharmacokinetic studies in rats. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 879, 2885-2890.
12. Jin, Z., Borjihan, G., Zhao, R., Sun, Z., Hammond, G. B. and Uryu, T. (2009) Antihyperlipidemic compounds from the fruit of Piper longum L. Phytother Res. 23, 1194-1196.
13. Park, B. S., Son, D. J., Choi, W. S., Takeoka, G. R., Han, S. O., Kim, T. W. and Lee, S. E. (2008) Antiplatelet activities of newly synthesized derivatives of piperlongumine. Phytother Res. 22, 1195-1199.
14. Kim, K. S., Kim, J. A., Eom, S. Y., Lee, S. H., Min, K. R. and Kim, Y. (2006) Inhibitory effect of piperlonguminine on melanin production in melanoma B16 cell line by downregulation of tyrosinase expression. Pigment. Cell Res. 19, 90-98.
15. Bezerra, D. P., Pessoa, C., Moraes, M. O., Alencar, N. M., Mesquita, R. O., Lima, M. W., Alves, A. P., Pessoa, O. D., Chaves, J. H., Silveira, E. R. and Costa-Lotufo, L. V. (2008) In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species. J. Appl. Toxicol. 28, 599-607.
16. Sugo, T., Nakamikawa, C., Tanabe, S. and Matsuda, M. (1995) Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. J. Biochem. 117, 244-250.
17. Rao, L. V., Rapaport, S. I. and Lorenzi, M. (1988) Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71, 791-796.
18. Ghosh, S., Ezban, M., Persson, E., Pendurthi, U., Hedner, U. and Rao, L. V. (2007) Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J. Thromb Haemost 5, 336-346.
19. Philip-Joet, F., Alessi, M. C., Philip-Joet, C., Aillaud, M., Barriere, J. R., Arnaud, A. and Juhan-Vague, I. (1995) Fibrinolytic and inflammatory processes in pleural effusions. Eur. Respir. J. 8, 1352-1356.
20. Schleef, R. R., Bevilacqua, M. P., Sawdey, M., Gimbrone, M. A. Jr. and Loskutoff, D. J. (1988) Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J. Biol. Chem. 263, 5797-5803.
21. Hamaguchi, E., Takamura, T., Shimizu, A. and Nagai, Y. (2003) Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J. Pharmacol. Exp. Ther. 307, 987-994.
22. Quinn, C., Hill, J. and Hassouna, H. (2000) A guide for diagnosis of patients with arterial and venous thrombosis. Clin. Lab. Sci. 13, 229-238.
23. Lopez, S., Peiretti, F., Bonardo, B., Juhan-Vague, I. and Nalbone, G. (2000) Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152, 359-366.
24. Kim, T. H., Ku, S. K. and Bae, J. S. (2012) Antithrombotic and profibrinolytic activities of eckol and dieckol. J. Cell Biochem. 113, 2877-2883.
25. Lee, W., Yang, E. J., Ku, S. K., Song, K. S. and Bae, J. S. (2012) Anticoagulant activities of oleanolic acid via inhibition of tissue factor expressions. BMB Rep. 45, 390-395.
26. Kim, D. C., Ku, S. K. and Bae, J. S. (2012) Anticoagulant activities of curcumin and its derivative. BMB Rep. 45, 221-226.
27. Bae, J. S. and Rezaie, A. R. (2008) Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 100, 101-109.
28. Kim, S. Y., Kim, S., Kim, J. M., Jho, E. H., Park, S., Oh, D. and Yun-Choi, H. S. (2011) PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. BMB Rep. 44, 140-145.
29. Nowak, P., Zbikowska, H. M., Ponczek, M., Kolodziejczyk, J. and Wachowicz, B. (2007) Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thromb Res. 121, 163-174.
30. Dejana, E., Callioni, A., Quintana, A. and de Gaetano, G. (1979) Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb Res. 15, 191-197.